Swedish Orphan Biovitrum GmbH

DED2601V.HRB226770|LangenGermany|2005

Profit€10.5M

Revenue€200.7M

Employees104

Balance€131.7M

About

Swedish Orphan Biovitrum GmbH is a company based in Langen. It is registered in the commercial register of the München local court under HRB 226770. The company was founded in 2005. In 2024, the company reported revenue of €200,673,468 and employed 104 people.

ClassificationWZ 2025

No. 6 of 1,671 – Top Employers with 100 to 500 Staff

Source: German Commercial Register (Handelsregister) München Local Court, HRB 226770 (as of 2 September 2026)

Company Structure

Shareholders

Source: German Commercial Register (Handelsregister) München Local Court, HRB 226770 (as of 2 September 2026)

Company History

Management

Date	Event Type	Event
09.04.2018	Registered Seat Change	63225 Langen,
05.08.2016	Registered Seat Change	63225 Langen,
01.07.2016	Company Name Registered	Swedish Orphan Biovitrum GmbH

Date	Type	Change	Total Capital
01.07.2016	Share Capital Set	—	25.000 €

CPV categories

Pharmaceutical products

Date	Contract	Role	Counterparty	Value
29.9.2026	Vereinbarung gemäß § 130c Abs. 1 SGB V über die Gewährung von Rabatten für patentgeschützte Arzneimittel mit dem Wirkstoff Eftrenonacog alfa (Alprolix®) Supplier · AOK Baden-Württemberg	Supplier	AOK Baden-Württemberg	—
3.9.2026	Arzneimittelrabattvertrag nach § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V zu den Arzneimitteln Alprolix (B02BD04), Elocta (B02BD02) und Altuvoct (B02BD02) zur Behandlung der Hämophilie Supplier · AOK Sachsen - Anhalt	Supplier	AOK Sachsen - Anhalt	—
24.7.2026	Ex-Ante-Transparenzbekanntmachung § 130a Abs. 8 SGB V i.V.m. § 130c Abs. 1 SGB V ATC-Code: B02BD34; ATC-Code: B02BD32; ATC-Code B02BD45 Supplier · AOK Bayern - Die Gesundheitskasse	Supplier	AOK Bayern - Die Gesundheitskasse	—

Source: German Commercial Register (Handelsregister) München Local Court, HRB 226770 (as of 2 September 2026)

Financials

Key financial figures over time — Swedish Orphan Biovitrum GmbH
Year	Revenue	Profit	Balance	Employees
2024	€200,673,468	€10,525,553	€131,743,553	104
2023	€171,783,424	€8,881,346	€92,922,603	91
2022	€151,512,685	€5,129,509	€83,927,795	79
2021	€127,932,274	€4,681,329	€77,240,032	69
2020	€129,417,383	€4,283,023	€65,525,081	59
2019	€118,955,690	€2,852,743	€43,785,248	53
2018	€97,724,984	€2,465,161	€35,812,511	40
2017	€64,881,849	€1,650,607	€30,173,629	33
2016	€40,887,727	€1,369,487	€19,379,354	32
2015	€26,666,750	€603,848	€12,215,517	—

Source: German Company Register (Unternehmensregister)

Register Files

Current Printout (AD)

Chronological Printout (CD)

List of Shareholders

Articles of Association

Model Protocol

Registration Application

Source: German Commercial Register (Handelsregister) München Local Court, HRB 226770 (as of 2 September 2026)

Contact

Website:sobi.com

Email:Sign in to view

USt-IdNr.:DE249382732

Annual Financial Statements

Annual Report 2024Published on 2 March 2026

Annual Report 2023Published on 8 January 2025

Annual Report 2022Published on 4 June 2024

Annual Report 2021Published on 15 May 2023

Annual Report 2020Published on 12 April 2022

Annual Report 2019Published on 24 March 2021

Annual Report 2018Published on 25 March 2020

Annual Report 2017Published on 4 April 2019

Annual Report 2016Published on 7 March 2018

Source: German Company Register (Unternehmensregister)

Cost type	Amount	Share
Personnel Costs	€18,670,193	99.2%
Depreciation	€144,694	0.8%
Interest & Similar	€6,702	0.0%

Swedish Orphan Biovitrum GmbH

About

ClassificationWZ 2025

Company Structure

Company History

Financials

Register Files

Contact

Annual Financial Statements

Cost Distribution (2024)